IKT – inhibikase therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Inhibikase Therapeutics (NASDAQ:IKT) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Inhibikase Therapeutics (NYSE:IKT) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $6.00 price target on the stock.
Inhibikase Therapeutics (NYSE:IKT) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at Wall Str
Form 4 Inhibikase Therapeutics, For: Jan 05 Filed by: Iwicki Mark T
Form 4 Inhibikase Therapeutics, For: Jan 05 Filed by: Cabell Christopher
Form 4 Inhibikase Therapeutics, For: Jan 05 Filed by: McIntyre David
Form SCHEDULE 13G Inhibikase Therapeutics, Filed by: Trails Edge Capital Partners, LP
Form 8-K Inhibikase Therapeutics, For: Dec 19
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.